Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Tadashi Nagakura

Richard S Clark

Fumiyoshi Matsuura

Nobuhisa Watanabe

Kazunobu Kira

Atsushi Inoue

Kimiyo Tabata

Hironori Ikuta

Hiroshi Azuma

Kazuto Yamazaki

Nobuyuki Yasuda

Shinsuke Hirota

Seiji Yoshikawa

Tatsuo Horizoe

Takao Omae

Kazutomi Kusano

Toshihiko Kaneko

Shuhei Miyazawa

Fumihiro Ozaki

Osamu Asano

Norio Karibe

Hideyuki Adachi

Kazuki Miyazaki

Itaru Tsukada

Atsushi Kamada

Hiroki Ishihara

Eita Emori

Yoshimitsu Naoe

Kohtarou Kodama

Yasushi Okamoto

Takao Saeki

Toshimi Okada

Masahiro Sakurai

Atsushi Takemura

Mika Aoki

Takashi Satoh

Mika Koyanagi

A compound represented by the following general formula (1) or salts thereof or hydrates of the foregoing: wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen.

Triazolone derivatives

A Compound represented by the following general formula (1): wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen or salts thereof or hydrates of the foregoing.

A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R, R, Rand Reach independently represent hydrogen, etc.; Rrepresents optionally substituted phenyl, etc.; Rrepresents optionally substituted C6-10 aryl, etc.; and Zand Zeach independently represent hydrogen]

A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein Rrepresents hydrogen, Rrepresents optionally substituted phenyl, etc., Rrepresents optionally substituted C6-10 aryl, etc.].

2,3-dihydro-iminoisoindole derivatives

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof  These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.

Condensed imidazole derivatives

The present invention relates to use of 1-carbamoylazole derivatives as medicaments and pharmaceutical compositions containing 1-carbamoylazole derivatives as the active ingredient, based on their DPPIV inhibiting effects. The present invention provides a dipeptidyl peptidase IV inhibiting agent comprising a compound represented by the general formula (I): 

Pharmaceutical use of N-carbamoylazole derivatives

The present invention provides novel compounds exhibiting an excellent DPPIV inhibition effect. The compounds are represented by the formula: wherein, m is 0 or 1;

Xanthine derivative and DPPIV inhibitor

Amidino derivatives represented by the following general formula (I):{where X is a group represented by RSONR&#x2014; (wherein Rrepresents optionally substituted Caryl, etc. and Rrepresents hydrogen atom, etc.), etc., Arrepresents 2,6-naphthylene, etc., Rrepresents hydrogen atom, etc. and Y represents carboxyphenyl, etc.}and their pharmacologically acceptable salts or solvates.

Amidino derivatives and anticoagulants and thrombosis therapeutic agents containing them

Phthalazine compounds and therapeutic agents for erectile dysfunction

Phthalazine derivatives and remedies for erectile dysfunction

Growing community of inventors

Tsukuba, Japan

Tadashi Nagakura